Cagrilintide and semaglutide together drive record weight loss in global trial Retatrutide vs. Tirzepatide: The Next Gen GLP 1 Showdown Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Semaglutide vs Tirzepatide Pro Peptides Plus CagriTirz (Cagrilintide + Tirz) >99% Purity Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link